Avenzo Therapeutics and DualityBio Enter Exclusive Global License Partnership for EGFR/HER3 Antibody-Drug Conjugate

Avenzo Therapeutics and DualityBio Enter Exclusive Global License Partnership for EGFR/HER3 Antibody-Drug Conjugate

01/07/25, 2:06 PM
Industry
biopharma
therapeutics
biotechnology
Type
partnership
Avenzo Therapeutics and DualityBio have announced an exclusive license agreement for the development, manufacturing, and commercialization of AVZO-1418/DB-1418, a potential best-in-class EGFR/HER3 bispecific ADC. The agreement aims to target multiple solid tumor types and marks a significant collaboration in the field of oncology therapies.

Company Info

Company
Avenzo Therapeutics and Duality Biotherapeutics
Additional Info
Avenzo Therapeutics, Inc. is a clinical-stage biotechnology company developing next-generation oncology therapies. Duality Biotherapeutics is a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics.